Back to UBS Group AG UBS Group AG

QNCXQNCX
Showing 8 of 28 quarters

Position history for UBS Group AGUBS Group AG's holdings in QUINCE THERAPEUTICS INC

UBS Group AG holds 556 shares of QNCX (QUINCE THERAPEUTICS INC), worth $56 as of 2026-Q1. The position was decreased (-98.4% shares).

Current Value

$56

Current Shares

556

Total Value Change

-$304

Total Shares Change

+76

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q1
Latest
Decreased
556
-98.4%
$560.0%$0.10
0
2025-Q4
Increased
35,092
+2284.0%
$117,5580.0%$3.26
24
2025-Q3
Decreased
1,472
-48.3%
$2,3990.0%$1.61
0
2025-Q2
Increased
2,846
+303.1%
$4,6960.0%$1.55
16
2025-Q1
Decreased
706
-36.6%
$9390.0%$1.35
0
2024-Q4
Increased
1,114
+132.1%
$2,0830.0%$1.85
13
2024-Q3
Unchanged
480
0.0%
$3730.0%$0.80
0
2024-Q2
Decreased
480
-5.0%
$3600.0%$0.75
0

Other major holders of QNCX: Capital World Investors, Capital International Investors, Capital Research Global Investors

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used